Chusny Syndrome

Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999 48 1856-1862. 38. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000 101 1780-1784. 39. Festa A, D'Agostino Jr R, Howard G, Mykkanen, L,...

Q

Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes A systematic review and meta-analysis. Diabetes Care 1999 22(suppl 2) B35-B39. 22. Lebovitz HE. The effect of the postprandial state on nontraditional risk factors. Am J Cardiol 2001 88(Suppl) 20H-25H. 23. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The association between a family history of type 2 diabetes and coronary artery disease in a type 1...

Huf

The characteristic abnormality of lipoprotein metabolism S in patients with syndrome X is hypertriglyceridemia, usually associated with a low-HDL cholesterol concentration, increased postprandial lipemia, and small, dense LDL particles. The use of fibric acid derivatives in patients with syndrome X will significantly lower plasma TG concentrations, as well as improve all of J the abnormalities associated with hypertriglyceridemia. In addition, there is now evidence that the use of...

Harold E Lebovitz

State University of New York Health Science Center at Brooklyn, Brooklyn, New York Diabetes mellitus is a syndrome in which blood glucose levels are inappropriately high for the individual's physiological state. In most populations both fasting and postprandial plasma glucose levels are continuous variables that are skewed toward the higher range. The differentiation between normal and abnormal is therefore arbitrary and must be defined by additional criteria. Diabetic retinopathy is the most...

Info

The treatment of hypercholesterolemia has undergone a revolution during the past 12 years with the availability of potent, safe HMG-CoA reductase inhibitors, a also known as statins. Lovastatin, pravastatin, fluvastatin, simvastatin, atorva-statin, and cerivastatin are available drugs in this category in the United States. They inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This results in both decreased hepatic production of apo B-containing lipoproteins and...

Overcoming the Manifestations of Syndrome X

Although therapeutic efforts aimed at enhancing insulin sensitivity may be limited, there is no reason to adopt a nihilistic approach to attenuating the CHD risk lt j factors in patients with syndrome X. Indeed, there are both dietary and pharmacological interventions that can substantially reduce the manifestations of syndrome X. As indicated earlier, weight loss will significantly improve insulin sensitivity in overweight, insulin-resistant individuals. However, not all overweight patients...

The Coagulation System And Diabetes Mellitus

The final common pathway resulting from activation of the coagulation system is generation of thrombin and thrombin-mediated formation of fibrin from fibrin-ogen. Generation of thrombin depends on activation of procoagulant factors and is limited by antithrombotic factors and inhibitors. A marker of thrombin activity is fibrinopeptide A FPA , released when fibrinogen is cleaved by thrombin. This peptide has a very short half-life in the circulation because it is cleared promptly by the kidneys....

Metabolic Syndrome

The metabolic abnormalities associated with DM are well recognized and include insulin resistance or, more appropriately, dysinsulinemia , hyperglycemia, hypertension, and dyslipidemia. These factors are associated with a panoply of biological perturbations that result in endothelial dysfunction with impaired coronary flow reserve, increased platelet activity, increased thromboxane A2 secretion, higher fibrinogen and factor VII levels, lower antithrombin III and plasma fi- S brinolytic...